NewcelX (NCEL) vs Quoin Pharmaceuticals (QNRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
NewcelX (NCEL) has outperformed Quoin Pharmaceuticals (QNRX) over the past year, losing 22.3% versus a loss of 82.1%. Over five years, NCEL leads with a -99.7% price change compared with -100.0% for QNRX. Quoin Pharmaceuticals is the larger company by market cap ($15.8 million vs $14.7 million), about 1.1 times the size.
On valuation, NewcelX trades at a lower trailing P/E (4.9x vs 7.5x for Quoin Pharmaceuticals).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NCEL | QNRX |
|---|---|---|
| Share price | $2.54 | $3.28 |
| Market cap | $14.67M | $15.76M |
| 1-day change | -5.58% | -2.35% |
| YTD return | +33.68% | -77.27% |
| 1-year return | -22.32% | -82.07% |
| 5-year return | -99.65% | -99.99% |
| P/E ratio (TTM) | 4.88 | 7.45 |
| EPS (TTM) | $0.52 | $0.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-8.30M | $-15.80M |
| 52-week high | $5.12 | $23.50 |
| 52-week low | $1.83 | $3.18 |
| Distance from 52-week high | -50.39% | -86.04% |
| Analyst consensus | none | none |
| Avg. price target upside | +805.51% | +565.55% |
| Average volume | 13.34K | 541.26K |
| Shares outstanding | 5.78M | 4.80M |
| Employees | 9 | 4 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NCEL has outperformed QNRX by 59.7 percentage points over the past year.
- Quoin Pharmaceuticals trades at a higher earnings multiple (7.5x vs 4.9x trailing P/E).
About NewcelX
NCEL stock →NewcelX Ltd., a biopharmaceutical company, engages in developing transformative stem-cell-derived therapies for Diabetes. The company develops NCEL-101, a cellular therapy product based on enriched pancreatic islet-like clusters for the treatment of Type 1 diabetes and Type 2 insulin dependent diabetes; AstroRx, an off-the-shelf cryopreserved cell therapy product for the treatment of Amyotrophic Lateral Sclerosis and neurodegenerative indications; and Dual Orexin-Receptor Agonist (DOXA), a small molecules platform for the treatment of sleep disorders, Neurodegenerative/ neuroinflammation diseases, and Diabetes Associated Neurological Disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees
About Quoin Pharmaceuticals
QNRX stock →Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion, which is in phase 2 to treat netherton syndrome (NS); phase 1 in to treat peeling skin syndrome; and in pre-clinical stage to treat SAM syndrome and ichthyosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
NCEL vs QNRX FAQ
Which is bigger, NewcelX or Quoin Pharmaceuticals?
Quoin Pharmaceuticals (QNRX) is larger, with a market capitalization of $15.76M compared with $14.67M for NewcelX (NCEL).
Which stock has performed better over the past year, NCEL or QNRX?
NCEL returned -22.32% over the past 12 months, compared with -82.07% for QNRX (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, NCEL or QNRX?
NCEL has the lower trailing P/E at 4.9, versus 7.5 for QNRX. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are NewcelX and Quoin Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.